Nicole DeFeudis

All selected drugmakers agree to second round of price negotiations under the IRA The second round of Medicare price negotiations is now underway for all 15 selected drugs with signed agreements in place from the manufacturers of those drugs.

The second round of Medicare price negotiations is now underway for all 15 selected drugs with signed agreements in place from the manufacturers of those drugs. endpts.com/all-selected...

Trump’s HHS defends Biden-era stance on 340B rebate models The Trump administration defended HHS’ rejection of drugmakers' 340B rebate models “at this time,” but suggested that the agency could be open to further consideration.

The Trump administration defended HHS’ rejection of drugmakers’ 340B rebate models “at this time." But when it comes to the companies’ proposed models, the agency specified that it “never said never.” endpts.com/trumps-hhs-d...

Live updates: Makary likely a lock for next FDA chief after breezy Senate hearing Live updates from the Senate nomination hearing for Martin Makary, Trump's pick to lead the FDA.

“I do believe that any child who dies of a vaccine-preventable illness is a tragedy in the modern era,” FDA nominee Marty Makary said during a Senate hearing today. Read more here: endpts.com/makary-heari...

Judge grants new nationwide block on NIH payment cuts A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law.

A federal judge on Wednesday blocked the NIH from issuing a cap on indirect cost payments for grantees after finding that the challengers are likely to show the cuts conflict with the law. endpts.com/judge-grants...

Live updates: Trump NIH pick Bhattacharya sails through Senate hearing, sidestepping controversy Trump's NIH nominee Jayanta

Trump's NIH pick Jay Bhattacharya appears headed for a relatively easy Senate confirmation, following a two-hour hearing on Wednesday. The @endpts crew has minute-by-minute updates here: endpts.com/bhattacharya...

Eli Lilly expands Zepbound single-dose vial options at lower price Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain patients.

Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain patients.

endpts.com/eli-lilly-ex...

NIH’s funding cut plan poses challenges for researchers despite court halt An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it.

An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it.

endpts.com/nihs-funding...

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far tougher day at a second Senate hearing on Thursday ...

Our take: "A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far tougher day at a second Senate hearing on Thursday." Read our @endpts.com wrap, complete with comments throughout today's hearing. endpts.com/kennedy-hear...

Takeda CEO Christophe Weber to retire in June 2026, Julie Kim to take over Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker.

Takeda CEO Christophe Weber will step down next June. Julie Kim, the current president of Takeda’s US business unit, will succeed Weber and will be the company’s first female CEO.

endpts.com/takeda-ceo-c...

RFK blog: Kennedy survives Senate grilling, with no bombshells to derail HHS confirmation Through a contentious three-and-a-half-hour hearing, Robert F. Kennedy Jr. emerged relatively unscathed as the Senate considers his nomination for HHS secretary. Democratic senators grilled Kennedy ov...

My Endpoints colleagues shared minute-by-minute updates on the Senate confirmation hearing for Robert F. Kennedy Jr. today. Check it out here:

endpts.com/kennedy-hear...

Trump administration makes first comments on how it will run IRA drug negotiations The Trump administration said on Wednesday it will consider

The Trump administration said it will consider “opportunities to bring greater transparency” to the Medicare drug price negotiation process under the Inflation Reduction Act. CMS said it intends to get input from stakeholders.

endpts.com/trump-admini...

AstraZeneca and Daiichi Sankyo's Enhertu approved in 'ultralow' HER2 patients AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer patients with very low levels of HER2 protein.

AstraZeneca and Daiichi Sankyo redefined how breast cancer patients are classified when Enhertu was approved for HER2-low patients. Now they're expanding to "ultralow" patients.

endpts.com/astrazeneca-...

Novo Nordisk asks Third Circuit to expedite IRA case as participation deadline looms Novo Nordisk is asking a federal appeals court to make haste on its case challenging the Inflation Reduction Act's drug pricing provisions.

Novo Nordisk is asking a federal appeals court to hurry up on its case challenging the Inflation Reduction Act’s drug pricing provisions.

endpts.com/novo-nordisk...

'No miracles': What Regeneron's George Yancopoulos really thinks of AI SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine. Agreeing to

NEW: I talked with George Yancopoulos on what he really makes of today's moment for AI

In his typical style, he has a few opinions on the topic:
endpts.com/regeneron-cs...

AstraZeneca exec stresses Calquence's patent life ahead of next Medicare negotiations AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But this time around, the company says it’s dealing with a whole different set of...

AstraZeneca says it plans to participate in another round of Medicare negotiations under the IRA. But a company executive told me it's dealing with a whole new set of considerations this time around:

endpts.com/astrazeneca-...

Teva says it has a 'unique position' in latest IRA challenge Teva is the latest drugmaker to file suit against Medicare negotiations. But unlike other companies that have challenged the inclusion of their drugs in negotiations, Teva says its case is unique.

Teva, which has Austedo on the list, filed suit against the IRA yesterday. Here's why the company said it's in a "unique position" to challenge Medicare negotiaitons: endpts.com/teva-says-it...

Ozempic makes list for next round of Medicare drug price negotiations Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare negotiation program under the Inflation Reduction Act, following repeated ...

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare negotiation program under the Inflation Reduction Act. See the rest of the list here:

endpts.com/novo-nordisk...

Biogen offers to buy out struggling neuro partner Sage Therapeutics Biogen has made an offer to acquire its partner Sage Therapeutics, according to a Friday evening regulatory disclosure, following months of setbacks by the smaller company that have led to a long slid...

A pre-JPM Friday firehose of news:

Four biotechs emerge with $800M: endpts.com/four-biotech...

Former top Moderna scientist's new startup: endpts.com/modernas-for...

Obesity drug startup Metsera files IPO: endpts.com/obesity-drug...

Biogen offers to buy partner Sage: endpts.com/biogen-offer...

DNA edit leads to apparent cure in infant; CDER director to step down; More biotechs emerge with assets from China; and more Endpoints Weekly reports on iECURE's gene therapy success for OTC deficiency, FDA CDER director Patrizia Cavazzoni's departure, and Verdiva Bio's $411M launch with Sciwind assets.

The @endpts.com Weekly has a new look! If you haven't already, sign up here to get our weekly recap of can't-miss biopharma news in your inbox on Saturday mornings: endpts.com/subscribe/

endpts.com/dna-edit-lea...